{
  "api": "assay-systems/v1",
  "key_tier": "none",
  "retrieved": "2026-10-16T16:29:12Z",
  "source": "Assay Systems register, https://assay-systems.com/register/",
  "access_notice": "On 15 November 2026, automated access to assay-systems.com closes. After that date, access is available only under a paid annual subscription contract. Contact: contact@assay-systems.com",
  "data": {
    "id": "ASY-CA-1E8K5SJ1DG",
    "type": "grant",
    "country": "ca",
    "name": "BC Cancer, part of the Provincial Health Services Authority: federal grants and contributions",
    "url": "https://assay-systems.com/register/ca/grants/r/bc-cancer-part-of-the-provincial-health-services-authority/",
    "summary": "7 federal grant and contribution agreements worth $2.9M with BC Cancer, part of the Provincial Health Services Authority, 2020–2024.",
    "figures": [
      {
        "label": "agreements",
        "value": 7,
        "unit": "count"
      },
      {
        "label": "value",
        "value": 2900000,
        "unit": "money",
        "currency": "CAD",
        "approximate": true,
        "display": "$2.9M"
      },
      {
        "label": "departments",
        "value": 1,
        "unit": "count"
      },
      {
        "label": "programs",
        "value": 2,
        "unit": "count"
      }
    ],
    "text": [
      "This project builds on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical trial using a made-in-Canada CD19 CAR T-cell therapy. The goal over the next 18 months is to build much-needed capacity in point-of-care (POC) manufacturing to support the clinical roll-out of novel CAR T-cell products and other personalized cell therapy products with the addition of three new POC manufacturing and clinical sites across Canada. In parallel, and with direct involvement of the NRC, it w",
      "This project build on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical trial using a made-in-Canada CD19 CAR T-cell therapy. The overarching goal of the Project is to build much needed capacity in point-of-care (POC) manufacturing to support the clinical rollout of novel CAR T-cell products and other personalized cell therapy products with the addition of new POC manufacturing and clinical sites. The Conconi Family Immunotherapy Lab (CFIL) at BC Cancer is the first of fou",
      "Immunotherapy has yielded disappointing results against ovarian cancer, prompting the need for bold new approaches. Chimeric Antigen Receptor (CAR) T cells have proven phenomenally successful against blood cancers but show poor efficacy against solid tumours. The NRC has created a nanobody-based, mesothelin-specific CAR (MesoCAR) to treat ovarian, pancreatic and other cancers. With Innovakine Therapeutics, the PI has developed an engineered cytokine receptor system that enables potent, clinician-controlled amplification of T cell responses in vivo. It is proposed to combine these technologies",
      "Designing a drug for a specific disease type is highly challenging due to tremendous molecular search space and limited understanding about the disease of interest. Successful discovery of a medicine for a target (gene/protein/pathway) usually last for many years and costs a private pharmaceutical organization billions of dollars, which in turn determines the unaffordable price of medicines in the Canadian and global markets. The emerging of massive biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provide an unpreced",
      "The main goal of this work is to create a made-in-Canada clinical ready approach for genome editing of CAR-T for cancer immunotherapy. The project aims to enhance the potency of single-domain antibody (sdAb) targeted CAR-Ts being developed by the Cell and Gene Therapy program, through site specific integration into rationally selected gene loci under conditions that are conducive to GMP CAR-T manufacture.",
      "This project will develop a lead candidate anti-CD22 CAR (Chimeric Antigen Receptor) comprising a camelid antibody derived anti-CD22 binding domain (developed by NRC) in the context of a CAR backbone and lentiviral vector system (developed by BC Cancer), suitable for inclusion in a CTA (Clinical Trial Application) submission to Health Canada",
      "Advances exploratory research under the New Beginnings Initiative"
    ],
    "records": [
      {
        "name": "grants and contributions register",
        "url": "https://assay-systems.com/register/ca/grants/"
      },
      {
        "name": "Vancouver East",
        "url": "https://assay-systems.com/register/ca/grants/riding/59036-vancouver-east/"
      },
      {
        "name": "National Research Council Canada",
        "url": "https://assay-systems.com/register/ca/grants/department/national-research-council-canada/"
      },
      {
        "name": "Vancouver Granville",
        "url": "https://assay-systems.com/register/ca/grants/riding/59038-vancouver-granville/"
      }
    ],
    "assay_record": "ASY-CA-1E8K5SJ1DG",
    "cite_as": "Assay Systems, \"BC Cancer, part of the Provincial Health Services Authority: federal grants and contributions\", https://assay-systems.com/register/ca/grants/r/bc-cancer-part-of-the-provincial-health-services-authority/"
  }
}